Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate glycemic control with diet, and insulin monotherapy, or insulin and oral hypoglycemic agent.

• Phase: Phase 4

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Treatments: Mitiglinide

Criteria

Inclusion Criteria:

• Patients who has been receiving dietary therapy and a stable dose and regimen of insulin over 8 weeks before at the time of an observation term start

• Patients whose HbA1c at the time of an observation term start is 7.5% or more and less than 10.0%

Exclusion Criteria:

• Type 1 Diabetes Mellitus

• Patients with serious diabetic complications and other serious complications